Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of cAd3-EBO S Ebola vaccine in healthy adults
NCT04041570Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jul 2019
- Primary completion
- Sep 2020
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of cAd3-EBO S in Ebola virus disease (EVD) (2 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Number of Participants Reporting Local Reactogenicity Signs and Symptoms at 7 days, Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms at 7 days and 3 more. Started Jul 2019; status: completed.
02
Drugs
cAd3-EBO S
03
Conditions
Ebola virus disease (EVD)
Beyond the preview
Go deeper on NCT04041570.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04041570.